SG142116A1 - Antihypersensitive combination of valsartan and calcium channel blocker - Google Patents
Antihypersensitive combination of valsartan and calcium channel blockerInfo
- Publication number
- SG142116A1 SG142116A1 SG200300082-5A SG2003000825A SG142116A1 SG 142116 A1 SG142116 A1 SG 142116A1 SG 2003000825 A SG2003000825 A SG 2003000825A SG 142116 A1 SG142116 A1 SG 142116A1
- Authority
- SG
- Singapore
- Prior art keywords
- hypertension
- diabetic
- combination
- renal
- valsartan
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 3
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract 3
- 239000000480 calcium channel blocker Substances 0.000 title abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 3
- 229960004699 valsartan Drugs 0.000 title abstract 3
- 206010020772 Hypertension Diseases 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010003662 Atrial flutter Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11389398A | 1998-07-10 | 1998-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG142116A1 true SG142116A1 (en) | 2008-05-28 |
Family
ID=22352165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200300082-5A SG142116A1 (en) | 1998-07-10 | 1999-07-09 | Antihypersensitive combination of valsartan and calcium channel blocker |
Country Status (31)
| Country | Link |
|---|---|
| EP (3) | EP2322174B1 (cs) |
| JP (1) | JP2002520274A (cs) |
| KR (2) | KR100550167B1 (cs) |
| CN (2) | CN1234357C (cs) |
| AT (1) | ATE371448T1 (cs) |
| AU (1) | AU753486B2 (cs) |
| BE (1) | BE2016C011I2 (cs) |
| BR (1) | BR9912021A (cs) |
| CA (2) | CA2678722C (cs) |
| CY (4) | CY1107779T1 (cs) |
| CZ (2) | CZ299429B6 (cs) |
| DE (2) | DE69936992T2 (cs) |
| DK (2) | DK1096932T3 (cs) |
| ES (2) | ES2289814T3 (cs) |
| FR (1) | FR16C0008I2 (cs) |
| HU (1) | HU229383B1 (cs) |
| ID (1) | ID27664A (cs) |
| IL (3) | IL140665A0 (cs) |
| LU (2) | LU91358I2 (cs) |
| NL (2) | NL300290I2 (cs) |
| NO (2) | NO331802B1 (cs) |
| NZ (2) | NZ527598A (cs) |
| PL (1) | PL194604B1 (cs) |
| PT (2) | PT1096932E (cs) |
| RU (3) | RU2450813C2 (cs) |
| SG (1) | SG142116A1 (cs) |
| SI (2) | SI2322174T1 (cs) |
| SK (1) | SK285863B6 (cs) |
| TR (1) | TR200100062T2 (cs) |
| WO (1) | WO2000002543A2 (cs) |
| ZA (1) | ZA200100232B (cs) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2289814T3 (es) | 1998-07-10 | 2008-02-01 | Novartis Pharma Ag | Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio. |
| IL143233A0 (en) * | 1998-12-23 | 2002-04-21 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| RU2239454C2 (ru) * | 1999-04-28 | 2004-11-10 | Такеда Кемикал Индастриз, Лтд. | Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии |
| JP2001089393A (ja) * | 1999-07-21 | 2001-04-03 | Takeda Chem Ind Ltd | 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤 |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| ES2246894T3 (es) | 1999-08-30 | 2006-03-01 | Sanofi-Aventis Deutschland Gmbh | Ramipril para la prevencion de sucesos cardiovasculares. |
| AU2001235364A1 (en) | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Tetrahydronaphtalene derivatives and their use |
| WO2001062740A1 (en) * | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Mibefradil analogues and their use |
| PE20020082A1 (es) * | 2000-04-12 | 2002-02-21 | Novartis Ag | Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1) |
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| BR0108823A (pt) * | 2000-12-29 | 2002-12-10 | Osmotica Corp | Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| EP1448190A2 (en) * | 2001-10-18 | 2004-08-25 | Novartis AG | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| EP1628663B1 (en) | 2003-05-15 | 2009-07-29 | Roskamp Research llc | Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| BRPI0410374A (pt) * | 2003-05-16 | 2006-06-13 | Novartis Ag | composição farmacêutica que compreende valsartano |
| RU2255740C2 (ru) * | 2003-07-02 | 2005-07-10 | Научно-исследовательский институт кардиологии Томского научного центра СО РАМН | Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса |
| US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| WO2005053687A1 (en) * | 2003-11-25 | 2005-06-16 | Novartis Ag | Combination of organic compounds |
| US20050187262A1 (en) * | 2004-01-12 | 2005-08-25 | Grogan Donna R. | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| ATE526965T1 (de) | 2005-04-15 | 2011-10-15 | Res & Innovation S P A | Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| GB0520405D0 (en) * | 2005-10-07 | 2005-11-16 | Imp College Innovations Ltd | Biological agents and method |
| JP2009514961A (ja) * | 2005-11-08 | 2009-04-09 | ノバルティス アクチエンゲゼルシャフト | アンギオテンシンｉｉ受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| RU2329805C2 (ru) * | 2006-08-28 | 2008-07-27 | Илья Николаевич Медведев | Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| RU2338527C1 (ru) * | 2007-02-26 | 2008-11-20 | Илья Николаевич Медведев | Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом |
| TWI500422B (zh) | 2007-10-05 | 2015-09-21 | Alzheimer S Inst Of America Inc | 以（－）－尼代地平（ｎｉｌｖａｄｉｐｉｎｅ）對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法 |
| CN101433536A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和沙坦类药物的治疗组合物 |
| MX2010007281A (es) * | 2007-12-31 | 2010-10-05 | Lupin Ltd | Composiciones farmaceuticas de amlodipina y valsartan. |
| WO2010006103A1 (en) * | 2008-07-10 | 2010-01-14 | Ore Pharmaceuticals Inc. | Method for enhancing cognition or inhibiting cognitive decline |
| RU2382644C1 (ru) * | 2008-11-05 | 2010-02-27 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью |
| RU2398581C1 (ru) * | 2009-05-28 | 2010-09-10 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) | Способ лечения больных гипертрофической кардиомиопатией |
| EP2536396B1 (en) | 2010-02-16 | 2016-08-10 | KRKA, D.D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
| IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
| UA110244C2 (en) * | 2011-04-12 | 2015-12-10 | Boryung Pharm | Antihypertensive pharmaceutical composition |
| RU2014109074A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ |
| WO2013147137A1 (ja) * | 2012-03-30 | 2013-10-03 | 味の素株式会社 | 心不全の治療剤 |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| US20180071272A1 (en) * | 2014-10-23 | 2018-03-15 | The Trustees Of The University Of Pennsylvania | Novel chronotherapy based on circadian rhythms |
| RU2616213C2 (ru) * | 2015-07-10 | 2017-04-13 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте |
| PL3368080T3 (pl) * | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
| CN105287550A (zh) * | 2015-11-19 | 2016-02-03 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/非洛地平复方制剂及其制备方法 |
| US20230218583A1 (en) | 2020-04-17 | 2023-07-13 | Honeybrains, Llc | Compositions and methods for treating neuropsychiatric disorders |
| WO2021239106A1 (zh) * | 2020-05-28 | 2021-12-02 | 杭州起岸生物科技有限公司 | 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399578A (en) * | 1990-02-19 | 1995-03-21 | Ciba-Geigy Corp | Acyl compounds |
| US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| US5889020A (en) * | 1994-02-08 | 1999-03-30 | Ciba Vision Corporation | Treatment of normotensive glaucoma with angiotensin II antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654372A (en) * | 1986-01-10 | 1987-03-31 | Warner-Lambert Company | Method for using verapamil for treating stroke |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| NZ242724A (en) | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| WO1993017682A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| AU662066B2 (en) * | 1992-07-27 | 1995-08-17 | Nps Pharmaceuticals, Inc. | Calcium channel blocking polypeptide from agelenopsis aperta |
| US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| ATE198551T1 (de) * | 1993-07-15 | 2001-01-15 | Hoffmann La Roche | Pharmazeutische kombination, die einen hemmer des renin-angiotensin-systems und einen endothelin- antagonisten enthält |
| CA2184712A1 (en) * | 1994-03-17 | 1995-09-21 | Marc De Gasparo | Treatment of diabetic nephropathy with valsartan |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| ES2289814T3 (es) | 1998-07-10 | 2008-02-01 | Novartis Pharma Ag | Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio. |
-
1999
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/en not_active Revoked
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 EP EP07105179A patent/EP1870098A3/en not_active Withdrawn
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/en active IP Right Grant
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active Expired - Fee Related
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 EP EP99934647A patent/EP1096932B1/en not_active Revoked
- 1999-07-09 CA CA2678722A patent/CA2678722C/en not_active Expired - Lifetime
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko not_active Ceased
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
- 1999-07-09 CA CA002336822A patent/CA2336822C/en not_active Expired - Lifetime
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
-
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
-
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I1/el unknown
-
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
-
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
-
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
-
2016
- 2016-03-07 LU LU92992C patent/LU92992I2/xx unknown
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown
- 2016-03-07 CY CY2016006C patent/CY2016006I1/el unknown
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399578A (en) * | 1990-02-19 | 1995-03-21 | Ciba-Geigy Corp | Acyl compounds |
| US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| US5889020A (en) * | 1994-02-08 | 1999-03-30 | Ciba Vision Corporation | Treatment of normotensive glaucoma with angiotensin II antagonists |
Non-Patent Citations (4)
| Title |
|---|
| AMERICAN HEART J. * |
| HUMAN HYPERTNSION * |
| PHARMACOL * |
| WORLD HEALTH ORGANISATION-INTERNATIONAL SOCIETY OF HYPERTENSION GUIDELINES FOR THE MANAGEMENT OF HYPERTENSION * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG142116A1 (en) | Antihypersensitive combination of valsartan and calcium channel blocker | |
| NL300811I2 (cs) | ||
| EP1507558B8 (en) | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |